Aventis Pharmaceuticals Inc.

Sanofi

Brian L Pedgrift

Tahir Nadeem Majid

Michael L Edwards

Paul Joseph Cox

Shelley Amendola

Christopher D Edlin

Andrew David Morley

Herve Bouchard

Stephanie Deprets

Charles J Gardner

Timothy A Gillespy

Frank Halley

Didier Babin

John Charles Reader

Dominique Damour

Conception Nemecek

Francois Clerc

Michael Cherry

Chantal Carrez

Dorothea Kominos

Laurence Gauzy

Justine Yeun Quai Lai

Nawaz Mohammed Khan

Stanly John

Olivier Houille

Alain Le-Brun

Lloyd J Payne

Daniel N A Bezard

Brian S Freed

Barbara S Rauckman

Martin Smrcina

David John Aldous

Iain M McLay

Sukanthini Thurairatnam

Tieu-Binh Le

Bernard Baudoin

John Ziqi Jiang

Jeffrey Stephen Sabol

Jean Merrill

Nicola Collar

Gerard Charles Rosse

Christopher Loren Vandeusen

David Squire Thorpe

Suzanne C Aldous

Lan Mu

Christopher L Vandeusen

Jianhong Zhao

William Shelly Wire

Corey Hopkins

Thomas Joseph Caulfield

Stephanie D Deprets

Friederike Wirtz-Brugger

James R Pribish

Jennifer Williford Clemens

Michael W Fennie

Robert S Francis

Antonio Daniel Ramos

Grzegorz T Stoklosa

The present invention relates to novel compounds of the formula Ia: in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, wherein the substituents are as described herein. The inventive compounds have CXCR5 inhibitory activity, and are particularly useful in treating or preventing various inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, lupus, Crohn's Disease, associated with the modulation of the human CXCR5 receptor.

Substituted benzoylamino-indan-2-carboxylic acids and related compounds

The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Benzimidazoles

This invention is directed to a compound of formula (I): wherein R, R, R, Rand Lare as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).

Pyrimidine hydrazide compounds as PGDS inhibitors

The invention is directed to physiologically active compounds of general formula (I):&#x2014; and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Azaindoles for inhibiting aurora2 and other kinases

Compounds of the formula and N-oxides, prodrugs, acid bioisosteres, pharmaceutically acceptable salts or solvates of such compounds, or N-oxides, prodrugs, or acid bioisosteres of such salts or solvates, to compositions comprising such compounds, and methods of treatment comprising administering, to a patient in need thereof, such compounds and compositions.

Pyrrolopyrimidines

Compounds of the formula I are suitable for producing pharmaceuticals for the prophylaxis and therapy of diseases whose course involves an increased activity of NIK.

Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders

The invention is directed to physiologically active compounds of general formula (I):and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Azaindoles

The invention is directed to physiologically active compounds of the general formula (Ix)and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Growing community of inventors

Morristown, NJ, United States of America

Brian L Pedgrift